PT  - JOURNAL ARTICLE
AU  - Julien, Jovan
AU  - Ayer, Turgay
AU  - Tapper, Elliot B
AU  - Barbosa, Carolina
AU  - Dowd, William
AU  - Chhatwal, Jagpreet
TI  - Effect of Increased Alcohol Consumption During COVID-19 Pandemic on Alcohol-related Liver Disease: A Modelling Study
AID  - 10.1101/2021.03.18.21253887
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.18.21253887
4099  - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253887.short
4100  - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253887.full
AB  - Objectives The burden of alcohol-related liver disease (ALD) is surging in the US. There is evidence that alcohol consumption increased during the early periods of the coronavirus disease-2019 (COVID-19) pandemic. We describe the impact of increased alcohol consumption on alcohol-related liver disease.Design Microsimulation modelSetting Model parameters estimated from publicly available data sources, including national surveys on drug and alcohol use and published studies informing the impact of alcohol consumption on ALD severity.Participants US residentsMethods We extended a previously validated microsimulation model that estimated the short- and long-term effect of increased drinking during the COVID-19 pandemic in individuals in the US born between 1950-2012. We modelled short- and long-term outcomes of current drinking patterns during COVID-19 (status quo) using survey data of changes in alcohol consumption in a nationally representative sample between February and April 2020. We compared these outcomes with a counter-factual scenario wherein no COVID-19 occurs, and drinking patterns do not change. Reported outcomes are for individuals aged 18-65.Main outcome measures ALD-related deaths inclusive of HCC mortality, the prevalence and incidence of decompensated cirrhosis and hepatocellular carcinoma, and disability-adjusted life-years (DALYs)Results Increases in alcohol consumption during 2020 due to the COVID-19 pandemic are estimated to result in to 8,200 [95% UI 7,700 – 8,700] additional ALD-related deaths (1% increase compared with the counter-factual scenario), 17,100 [95% UI 16,100 – 18,200] cases of decompensated cirrhosis (2% increase) and 1,100 [95% UI 1,100 – 1,200] cases of HCC (1% increase) between 2020 and 2040. Between 2020 and 2023, alcohol consumption changes due to COVID-19 will lead to 100 [100-200] additional deaths and 2,200 [2,200-2,300] additional decompensations in patients suffering from alcohol-related liver disease.Conclusions A short-term increase in alcohol consumption during the COVID-19 pandemic can substantially increase long-term ALD-related morbidity and mortality. Our findings highlight the need for individuals and policymakers to make informed decisions to mitigate the impact of high-risk alcohol drinking in the US.What is already known on this topicThe impact of an increase in alcohol consumption during coronavirus disease 2019 (COVID-19) on drinking trajectory changes and alcohol-related liver diseases is not known.Studies have reported increases in hospital admissions for alcohol-related liver disease or pancreatitis potentially related to COVID-19, increases in alcohol consumption, and exacerbation of pre-existing liver injury, though limited evidence exists for the long-term effect of increased drinking on alcohol-related liver cirrhosis and liver cancer in the USA.Added value of this studyOur study provides new data on liver disease morbidity and mortality associated with increased consumption of alcohol during the COVID-19 pandemic.Our study suggests that drinking changes associated with the COVID-19 pandemic it is expected to lead to increases in both mortality and morbidity in the long term. to 8,200 additional ALD-related deaths, 17,100 cases of decompensated cirrhosis, and 1,100 cases of HCC between 2020 and 2040 2Competing Interest StatementElliot Tapper has served as a consultant to Norvartis, Axcella, Kaleido, and Allergan, has served on advisory boards for Takeda, Mallinckrodt, Rebiotix, and Bausch Health, and has received unrestricted research grants from Gilead and Valeant. Jagpreet Chhatwal has served as a consultant to Novo Nordisk and partner at Value Analytics Labs. Turgay Ayer has served as a consultant to Merck and partner at Value Analytics Labs. No other author has a conflict of interest.Funding StatementThis study was funded by the American Cancer Society Research Scholar (grant RSG-17-022-01-CPPB), the Robert Wood Johnson Health Policy Research Fellowship (award number 74817), and the National Institutes of Health (grant K23DK117055). CB and WD would like to acknowledge financial support by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under Award Numbers R01AA024423. The funding agreements ensured the author independence in designing the study, interpreting the data and writing and publishing the report. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This manuscript was prepared using a limited‐access data set obtained from the National Institute on Alcohol Abuse and Alcoholism and does not reflect the opinions or views of NIAAA or the US Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study (Protocol H18459) obtained ethics approval through the institutional review board of Georgia Institute of Technology.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available.